Impact of effective prevention and management of febrile neutropenia

British Journal of Cancer

Volumn 101, Issue , 2009, Pages S23-S26

  Krell, D ^a   Jones, A L ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Cost; Febrile neutropenia; Prevention; Protocols; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; QUINOLONE;

BREAST CANCER; CANCER CHEMOTHERAPY; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEVER; GREAT BRITAIN; HUMANS; NEUTROPENIA; STATE MEDICINE;

EID: 70349208982     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605273     Document Type: Article

References (30)

1. Ali Z, O’Reilly S, Zahoor T, Schofield P, Malik Z (2008) Experience of f ebrile neutropaenia and secondary G-CSF prophylaxis during FEC_D chemotherapy in Merseyside and Cheshire Cancer Network. National Cancer Research Institute Cancer Conference; Abstract B67
2. Bonadonna G, Valagussa P, Moliternni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: 901–906
3. Cancer Research UK (2009) UK breast cancer incidence statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/(accessed May 2009)
4. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, Garcia- Garre E, Martin P, Bosch A, Lluch A (2006) Impact of chemotherapy doserelated factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol 24: Abstract 668
5. Cullen M, Baijal S (2009) Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer 101(Suppl 1): S11–S14
6. Dale DC, Cosler LE, Wolff DA, Culakova E, Poniwierski MS, Crawford J, Lyman GH, for the ANC study group (2006) Economic analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) use based on a risk model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 24: Abstract 6107
7. Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH (2008) Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11: 172–179
8. Fortner BV, Tauer K, Zhu L, Okon TA, Moore K, Templeton D, Schwartzberg L (2002) Medical visits for chemotherapy and chemotherapy- induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer 4: 22
9. Glaspy J, Hackett J, Flyer P, Dunford D, Liang B (2001) Febrile neutropaenia is associated with an increase in the incidence, duration and severity of chemotherapy toxicities. American Society of Hematology Annual Meeting
10. Gridelli C, Aapro MS, Barni S, Beretta GD, Colucci G, Daniele B, Del Mastro L, Di Maio M, De Petris L, Perrone F, Thatcher N, De Marinis F (2007) Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol 63: 53–64
11. Head J, Archer C, Harper-Wynne C, Sinha R, Ring A, Banner R, Sutherland S, Johnston S (2008) Rates of neutrpaenic sepsis with the use of adjuvant FEC100-Docetaxel (FEC100-T) chemotherapy in highrisk node-positive patients with early breast cancer; a UK perspective. National Cancer Research Institute Cancer Conference; Abstract B64
12. Herbst C, Naumann F, Kruse E, Knauel I, Schulz H, Bohlius J, Engert A (2008) Prophylactic antibiotics and G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy (Protocol). Cochrane Database Syst Rev 4: CD007107
13. Holmes J, Dunlop D, Hemmett L, Sharplin P, Bose U (2004) A costeffectiveness analysis of docetaxel in the second-line treatment of nonsmall cell lung cancer. Pharmacoeconomics 22: 581–589
14. Kelly S, Wheatley D (2009) Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 101(Suppl 1): S6–S10
15. Kuderer NM, Dale DS, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258–2266
16. Leonard RCF, Miles D, Thomas R, on behalf of the UK Breast Cancer Neutropenia Audit Group (2003) Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 89: 2062–2068
17. Lyman GH, Kuderer N, Green J, Balducci L (1998) The economics of febrile neutropaenia: implications for the use of colony-stimulating factors. Eur J Cancer 34: 1857–1864
18. Lyman GH, Lyman CH, Agboola O, for the ANC study group (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10: 427–437
19. Moore K, Crom D (2006) Hematopoietic support with moderately myelosuppressive chemotherapy regimens: a nursing perspective. Clin J Oncol Nurs 10: 383–388
20. National Cancer Peer Review Programme 2004–2007 (2008) National Report: an Overview of the Findings from the Second National Round of Peer Reviews of Cancer Services in England. NCPRN: London
21. National Chemotherapy Advisory Group (2009) Chemotherapy Services in England: Ensuring Quality and Safety. NCAG: London
22. National Confidential Enquiry into Patient Outcome and Death (2008) For Better, for Worse?. NCEPOD: London
23. Okon TA, Fortner BV, Schwartzberg I, Tauer KT, Durrence H, Kovacs A, Wheetly K, Woods C, Taylor D, Houts AC (2002) Quality of life (QOL) in patients with grade IV chemotherapy induced neutropenia (CIN). Proc Am Soc Clin Oncol 21: Abstract 2920
24. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O’Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ, NEAT Investigators and the SCTBG (2006) Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 355: 1851–1862
25. Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24: 5664–5671
26. Scaife J, Matthews R, Jenkins P (2008) Febrile neutropaenia in patients receiving TAC chemotherapy for breast cancer. National Cancer Research Institute Cancer Conference; Abstract BOA14
27. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24: 3187–3205
28. Trueman P (2009) Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review. Br J Cancer 101(Suppl 1): S15–S17
29. Verschraegen C, Vinh-Hung V, Cserni G, Gordon R, Royce ME, Vlastos G, Tai P, Storme G (2005) Modeling the effect of tumour size in early breast cancer. Ann Surg 241: 309–318
30. Zaman AAL, McGhie A, Shaikh G, Canney P, Fraser J (2008) DGH Experience of Adjuvant FE[100]C-D Chemotherapy in Node Positive Breast Cancer. NHS Greater Glasgow and Clyde: Glasgow